Incontinence News and Research

Latest Incontinence News and Research

AltheRx purchases all assets related to Solabegron from GlaxoSmithKline

AltheRx Inc., a privately-held clinical development company, announced today that it has purchased all assets related to Solabegron from GlaxoSmithKline. Solabegron is a highly selective and potent beta3-adrenoceptor agonist that has demonstrated positive results in Phase II clinical programs for the treatment of Overactive Bladder in women and Irritable Bowel Syndrome.

25 Mar 2011

JWOCN joins with CAET to expand its position within global community of nursing

The Journal of Wound, Ostomy and Continence Nursing has affiliated with the Canadian Association for Enterostomal Therapy, expanding its position within the global community of wound, ostomy and continence nursing.

24 Mar 2011

NeoTract initiates patient enrollment for UroLift System trial to treat prostrate cancer

NeoTract, Inc. a medical device company focused on developing urology devices, today announced that the first U.S. patients have been enrolled in a multinational trial of its UroLift® System at Western Urological Clinic in Salt Lake City, Utah.

23 Mar 2011

Astellas announces positive results from mirabegron phase III trials against OAB

Astellas Pharma Inc. today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder, show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition.

23 Mar 2011

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, today presented positive results from a Phase 1 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder and urge urinary incontinence.

23 Mar 2011

The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced the publication of results from a randomized-controlled clinical trial of the bulking agent, NASHA DX, a dextranomer suspended in stabilized, which was injected into the submucosa of the anal canal in patients with fecal incontinence.

19 Mar 2011

NAFC honors Florida's Cleveland Clinic physician with Continence Care Champion Award

The National Association For Continence awarded Gamal Ghoniem, MD, with the Rodney Appell Continence Care Champion Award at the Society for Urodynamics and Female Urology Awards Reception on March 4, held during the 2011 SUFU Winter Meeting in Phoenix, AZ.

16 Mar 2011

SCA report: 59% of women chooses wellbeing dimension as most important aspect

A majority of women in both emerging and more mature markets view wellbeing as the most important dimension of personal hygiene, even more so than staying healthy.

8 Mar 2011

Focused Ultrasound Surgery Foundation releases men's heath update on prostate cancer, BPH treatments

The Focused Ultrasound Surgery Foundation has released a special men's heath update in its February 2011 online newsletter.

23 Feb 2011

3M's Infection Prevention Division, Sage Products enter second agreement

Sage Products and 3M's Infection Prevention Division have entered into an agreement which includes sales representation of Sage Products by 3M in select international locations. The new agreement is the second collaboration announced by the two companies in recent months.

15 Feb 2011

FDA waives NDA filing fee for Antares' Anturol NDA

Antares Pharma, Inc. today announced the receipt from the U.S. Food and Drug Administration (FDA) of a waiver, on February 8, 2011, for the $1,500,000 New Drug Application (NDA) filing fee for Anturol® Gel for overactive bladder (OAB).

14 Feb 2011

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Myriad Genetics, Inc. announced today that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS™ molecular diagnostic test significantly predicts prostate cancer outcome.

10 Feb 2011

Study: Parkinson’s disease undermines language processing ability in Dutch native speaker patients

It is becoming more generally known that Parkinson's disease not only influences a patient's motor functions. Patients often also suffer from depression, fear and incontinence, for example. However, the disease also undermines the language processing ability. University of Groningen researcher Katrien Colman has found clear indications of this in Dutch native speaker patients.

9 Feb 2011

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

A genetic pattern could predict how aggressive prostate cancer is before treatment, and whether the disease will come back in men who have already been treated, according to research published1 in the Lancet Oncology.

9 Feb 2011

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy: injectable fluorescent peptides that cause hard-to-see peripheral nerves to glow, alerting surgeons to their location even before the nerves are encountered.

6 Feb 2011

New report identifies top research priorities related to Female Pelvic Medicine, Reconstructive Surgery

A set of consensus recommendations identifying top research priorities related to female pelvic floor disorders is presented in the January/February issue of Female Pelvic Medicine & Reconstructive Surgery, official journal of The American Urogynecologic Society.

4 Feb 2011

Invacare 2010 adjusted earnings per share increase 16% to $1.84

Invacare Corporation today announced its financial results for the quarter and year ended December 31, 2010 and provided guidance for 2011.

3 Feb 2011

Metamark announces Nature journal published landmark prostate cancer study results

Metamark Genetics, Inc., a privately-held oncology molecular diagnostics company, today announced results from a landmark prostate cancer study published as an Advance Online Publication in the journal Nature.

3 Feb 2011

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.

3 Feb 2011

Public services supporting California's low-income, disabled elderly is fragile, says study

The network of public services that supports California's low-income, disabled elderly is fragile, affecting the ability of these vulnerable residents to live independent lives in their own homes, according to a new study from the UCLA Center for Health Policy Research.

1 Feb 2011

Incontinence News and Research

Latest Incontinence News and Research

AltheRx purchases all assets related to Solabegron from GlaxoSmithKline

JWOCN joins with CAET to expand its position within global community of nursing

NeoTract initiates patient enrollment for UroLift System trial to treat prostrate cancer

Astellas announces positive results from mirabegron phase III trials against OAB

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence

NAFC honors Florida's Cleveland Clinic physician with Continence Care Champion Award

SCA report: 59% of women chooses wellbeing dimension as most important aspect

Focused Ultrasound Surgery Foundation releases men's heath update on prostate cancer, BPH treatments

3M's Infection Prevention Division, Sage Products enter second agreement

FDA waives NDA filing fee for Antares' Anturol NDA

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Study: Parkinson’s disease undermines language processing ability in Dutch native speaker patients

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

New report identifies top research priorities related to Female Pelvic Medicine, Reconstructive Surgery

Invacare 2010 adjusted earnings per share increase 16% to $1.84

Metamark announces Nature journal published landmark prostate cancer study results

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Public services supporting California's low-income, disabled elderly is fragile, says study

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Incontinence News and Research

Latest Incontinence News and Research

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in